Sarizotan

Drug Profile

Sarizotan

Alternative Names: EMD 128130

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Newron Pharmaceuticals
  • Class Antiparkinsonians; Antipsychotics
  • Mechanism of Action Dopamine D2 receptor partial agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Rett syndrome
  • Discontinued Drug-induced dyskinesia

Most Recent Events

  • 24 Oct 2016 Phase-II/III clinical trials in Rett syndrome in Italy (PO)
  • 21 Jul 2016 Phase-II/III clinical trials in Rett syndrome in USA (PO)
  • 13 Jun 2016 Newron Pharmaceuticals plans the phase II/III STARS trial in Rett syndrome in USA, India and Italy (NCT02790034)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top